Medical Billing Business Plan


Medical Billing Business Plan


Medical billing services exist today to help with the management of medical practices. These services help medical professionals with tedious details but seldom offer a way to significantly improve the practice’s bottom lines. Physicians 1st Billing and Claims will not only free office staff for more crucial tasks, but will also maximize return from insurance carriers.

National statistics indicate that only around 70% of insurance claims initially submitted on paper get paid by insurance carriers. Electronic submissions can raise the percentage of claims to around 98% with Physicians 1st Billing and Claims.

Additional statistics suggest that the current cost for a medical clinic to process insurance claims on patients is between $8.00-$10.00. Physicians 1st Billing and Claims can reduce these costs by 50 percent or more.

Statistics show that paper claims turnaround times can take up to 30-60 days, or even 90 days, which creates serious outstanding receivables. Physicians 1st Billing and Claims is able to have money in the doctor’s hands within 14-18 working days by electronically submitting claims. This reduces outstanding receivables and greatly improves cash flow.

Statistics show that there is a 30% rejection rate or suspension for paper insurance claims. This does not necessarily mean that claims are never paid. The only thing it means is that medical staff will have to fight with insurance carriers about payment. With the extensive editing performed on electronic claims prior to their transmission to carriers, this percentage is reduced to 2-3 percent. Claims are submitted accurately at 98 percent.

Many years ago, physicians were taught that they would be running a practice. Numerous administrative tasks were overlooked, including:

  • Keep current with all insurance regulations and specifications to ensure that claims are paid promptly
  • Concentrate your efforts on collecting receivables.
  • To ensure that fees are kept as low as possible for insurance carriers,
  • Procedure codes were current so that claims weren’t suspended or rejected.

For many offices, outstanding receivables grew tremendously and annual bad-debt write-offs became routine. Medical practices could ignore sound business practices because of their profit margins. In the past, medical practice complacency about industry changes is now a thing of the passé. Physicians’ heads raised and they began taking note of public opinions toward health care reform issues four years ago. Physicians are losing money due to the increasing number of managed-care organizations entering the industry. Physicians are becoming more aware of the need to improve their business processes in order to stay in business in the 21st Century. Physicians 1st Billing and Claims is ready to support local health providers in moving through the 20th and 21st centuries with sound business practices. This will help ensure that quality health care is provided for our families and the country.

Physicians 1st Billing and Claims has contributed over $9,000 towards this business. We would like to borrow another $5,000. This business plan is very important. This section explains how to use these funds.

1.1 Objectives

  1. To open one account by the end month two.
  2. 1500 claims per month to be processed 15.
  3. To be recognized as an expert in local medical reimbursement.
  4. To include additional services in addition to the initial offering of electronic claims submission.

    • Optimization of code
    • Managed care contract analysis.
    • Management of the entire practice.
    • Reporting tailored to your needs
    • Medical transcription.
    • Fee analysis
    • Medicare financial impact analysis.

1.2 Mission

Physicians 1st Billing and Claims (Patients 1st Billing and Claims) is a medical reimbursement consulting business that helps medical practices become more efficient and cost-effective by allowing them the ability to outsource their insurance processing and medical billing. We plan to provide a one-stop solution for all administrative needs of medical practice administration by 1998. We aim to make enough money to repay our loan to start our business and to continue to grow our service.

1.3 Keys to Success

The Federal Government has been encouraging the electronic submission of insurance claims by the health care sector since 1985. Statistics prove that electronic submission can save millions of dollars annually for the industry. Currently, electronic submissions are used to submit 95 percent of all claims for pharmaceuticals and 70 percent for hospital claims. Doctors and dentists are close behind at 25-30 percent.

The Federal Government is not happy about this situation and in 1990 Congress required that doctors file claims for all Medicare patients. Many doctors were not prepared for this deluge of paperwork. Eight years later, doctors still struggle to climb out from beneath the piles of paperwork. In 1996, the congress was hearing the motions to require electronic submission for all Medicare claims. No mandate was passed but the paperwork continues to mount up and as baby boomers near retirement age the paper problem will only get worse and those echoes will turn into screams. Over 1 trillion dollars in medical charges will be issued this year in the United States. This is equivalent to 9 billion medical claims. These mandates will force medical practices to comply. There are growing mountains of paperwork, and many aren’t equipped to manage the transition. It is sensible to outsource the process to professionals who are willing to save money, provide a faster return on insurance, and manage the claims with high accuracy. There aren&#8217 a lot of businesses that can say that they have the Federal Government backing them all the time.

Flexibility is another key to our success. Physicians 1st Billing and Claims knows that each medical practice has its own unique characteristics. Even practices of the same specialty will have different staff and offer different services. Physicians 1st Billing and Claims can evaluate each practice and suggest solutions to make it more efficient. Some people may require all our services. Others may choose to only use a handful. We will tailor our billing to meet the needs of each office.

Our diverse services are also key. Physicians 1st Billing and Claims provides a one-stop shopping experience for medical administrative services.

Medical Equipment Developer Business Plan


Medical Equipment Developer Business Plan


Medquip, Inc., a medical device company, is working to develop, patent, market and sell medical devices for niche markets. The participation of prominent gastroenterologists, surgeons, and physicians has already resulted in three devices. Seven patents have been incorporated. The company estimates $16million in annual sales for year three. The company is expecting to earn $50 million by year five. A top patent law firm has already filed patent applications for the company’s first three market entries.

The market segments are well defined and are all subject to high growth trends. One market is projected exceed $160 Million in the next three to five years. This market is endoscopic variceal (ligation) Medquip’s founder participated in the development of the market leader in this field. He has made significant improvements to the product. Another market addresses a well-defined and unanswered need in endoscopic surgery: the clearing of fundal pools of blood and tissue during surgical procedures. To fulfill the surgeons’ requirements, a novel and innovative design was developed.

The market is expected to start at $20 million, but it could grow to hundreds of millions once approvals for various surgical procedures are granted. Medquip plans to license the technology to a larger firm. The company matures by year three. If a licensing agreement is reached, the company can become profitable in year 1.

Mission

Medquip, Inc.’s mission is to develop, market, and patent new technologies in the field of medical devices. These technologies will each fill a market segment that is worth at least $20 million in potential sales. Each technology will address a specific medical need by either improving on an existing device or technology, or creating a device that meets a clear need. The product should be priced so that it appeals to managed-care markets, which emphasize the lowest total treatment costs.

Keys to Success

Medquip, Inc. is a company that has succeeded because of the following:

  1. Initial capitalization obtained.
  2. All filed patent applications
  3. The ability generate early revenue from markets outside of Europe.
  4. Licensing at the least one technology, and application to a major corporation in the field of medical devices.
  5. Get low interest loans or grants to fully finance product development, prototype manufacturing.
  6. Recruiting top-notch leaders before second round financing.
  7. FDA approves Visi-Band for marketing in the U.S. with a successful 510k approval
  8. To achieve a minimum 10% market share in the U.S. managed healthcare market, and generate $16 million in revenue in the second year, successful implementation of a sales and marketing plan.
  9. Product development has been increased and market share has continued to grow, resulting in a company with a $50m revenue by five years.

Objectives

The principal objectives of Medquip, Inc. are as follows:

  1. To reach a 10% market penetration in endoscopic variceal (ligation) by the third year.
  2. To earn $16million in revenues by year three.
  3. To raise $1 million in private seed capital in the first six months.
  4. To receive grants and loans at low interest rates from the government of Puerto Rico in an amount totaling $1.2million for one year.
  5. To license its technology for the obliteration/suction/irrigation market for $1 million dollars in year one.


Medical Equipment – Supplies Business Plan


Medical Equipment - Supplies Business Plan


This business plan was developed to help us present our company and potential partners to investors, employers, or suppliers. Zenergy Medical Industries, a start-up company, is initially focused on distribution of the most trusted therapeutic systems for residents of Homecare and assisted living facilities that are susceptible to complications from X. After building a market share in this product area, we plan to expand to offer additional products for managing and treating complications of the condition.

The market is currently being served inconsistently and poorly by a few local pharmacies. We will offer a regional, and ultimately national, network of clinical sales professionals, which will make us the partner of choice for large, geographically diverse Homecare and Assisted Living (A.L.) chains, and will make us attractive to potential supplier partners.

Potential Market

Two major markets are the ‘#8220’ at-risk residents in Homecare or Assisted Living. The potential revenue from Homecare is $59.6million, and there are an estimated 345.784 at-risk residents in Assisted Living.

Competitive Advantage

This market has all the technology needed to make our products. We will differentiate ourselves by adding value through our distribution strategy and channels, and our comprehensive product lines and programs that make working with us incredibly easy. We have unique market access because of our corporate accounts and our ability quickly to build a national (ultimately regional) field clinical sales staff. There is less competition from smaller local distributors and pharmacists, who do not approach the market in a coordinated or sophisticated manner.


Strategy

  1. Using relationships with decision makers at major homecare chains to gain unique access to sell into their facilities. This will enable us to offer ‘#8220’ pre-qualified sales opportunities to our clinical sales team.
  2. Establishing a strong national sales team for clinical services capable of building strong relationships to clinical decision makers at facility level.
  3. We create marketing strategies to position ourselves to be leaders in providing solutions for clinical problems.
  4. A unique mix of top suppliers will be used to gain distribution relationships and create a range of product solutions that address the many complications of the disease. We will provide a reliable channel of distribution for suppliers to help them penetrate the post-acute markets.

We will use the therapeutic system offering to gain entry into the market, and to build our business. Then, we’ll add complementary products that manage the diseases. Next, there will be other products that deal with managing heart disease or aging.

Financial Summary

The business owners will put their personal savings into the venture. We are seeking an additional short-term (3 year) loans, to supplement initial cash flows from sales for the first year. We expect to make a profit for the first year. By year three, this should increase substantially. Zenergy Medical Industries will be a highly respected company by the end of three years.

Objectives

  • To achieve the goals of sales growth by month six and at the end of year one. Aggressive gains in market share and average monthly revenues in year two.
  • To grow the contracted team to seven field-based clinical sales reps at month eight, and to twenty-five field clinical reps at year three.
  • To achieve net profit in year one, increasing in year two, by containing costs and meeting sales goals.
  • To begin paying Vice Presidents a regular salary starting in year two.
  • At 98% or more, to maintain customer satisfaction survey results for 90 days (% who would definitely buy again and definitely recommend us).

Mission

We offer post-acute treatment facilities with product solutions that can help with complications of X-related diseases. We take great pride helping to relieve the suffering that these conditions cause.

Keys to Success

  1. We offer a broad range of innovative and top quality products.
  2. We offered unrivalled clinical support at a regional (national level) to post-acute facilities.
  3. We are close to key decision-makers in the top post-acute chains and with clinicians and administrators at the facility level.
  4. We do an exceptional job of articulating the value of our products and solutions.We position ourselves in a clear, powerful, and memorable way in the marketplace.
  5. Our organization has a unique spirit which makes people want to work with us. Once people join us, they can’t imagine working anywhere else.

Medical Internet Marketing Business Plan


Medical Internet Marketing Business Plan


DocBuzz, Inc., is a medical marketing company that specializes in the sale of medical devices, pharmaceuticals, and biotechnical products. DocBuzz, Inc. is the only company of its kind; a business especially designed for doctors and the medical community, owned and operated by practicing physicians.

The pharmaceutical market is one of the most profitable industries, with revenue in excess of $96.3 billion annually. The problem the pharmaceutical industry faces is time. Time for research and development, time for branding, time for marketing and sales, time to gain the trust and acceptance of the medical community. In this industry, we can equate time with money.

Two other industries also have similar situations when it comes to their products. Those industries are the biotech and the medical device companies. While the revenues are not as great as what one will find within the pharmaceutical industry, these companies face heavy competition within their own individual industries.

DocBuzz, Inc., has developed a method that allows all of these industries to benefit from prelaunch marketing, product branding, and postlaunch sales support–all accomplished with the direct intervention of practicing physicians. DocBuzz, Inc. offers clients the opportunity to market directly with decision makers, and establishes credibility via our extensive network. Our e­detailing is the most cost-effective option of all services. Live conferences are available, 24 hours per day, seven days a săptămână. This service provides access to an array of current information, including new biotech developments, pharmaceutical products and medical devices.

The pharmaceutical, biotech and medical device industries will contract with DocBuzz, Inc., to provide marketing services, and because we are practicing physicians, we have immediate access to our colleagues. This allows us to communicate the message of these companies directly to the decision-makers at 75% off what these industries currently budget. DocBuzz, Inc., thanks to its unique incentive program, will provide additional revenue for physicians and other medical professionals.

DocBuzz has developed a winning strategy to provide the best and most up to date information to the medical community, while providing a method for these industries to announce, promote and market their products through respected practicing physicians. The medical community benefits by having the most current industry information available via the Internet. At the end of the eDetailing, they can request samples, additional information and/or a visit from a representative of pharma companies. Professionals on our medical panel can earn points by participating in our e-detailing and/or by referral of others who join our program.

Success Keys 1.1

DocBuzz, Inc., identified four key strategies that are critical to our success.

  1. To increase market acceptance of a product, and its prescribing patterns, the Internet technology was developed to improve the access of the prescribing physician to the pharmaceuticals.
  2. DocBuzz, Inc., uses a grass root approach to recruit and retain participating prescribing medical professionals through a value incentive referral point program (VIRP). DocBuzz, Inc., which is owned and operated by physicians, has the ability to understand and offer physician’s needs.
  3. DocBuzz, Inc. can provide evidence-based analysis for the pharmaceutical industry in order to justify the pharmaceutical investment in e-detailing.
  4. DocBuzz, Inc., expects to experience rapid, but controlled, growth in order for us to keep our quality service.

1.2 Mission

DocBuzz, Inc., provides a trusted, high-quality alternative for in-house sales and marketing resources to medical device, pharmaceutical, biotechnical, or biotechnical companies. DocBuzz, Inc., enhances sales and marketing ROI by helping physicians learn more about prelaunch, current, and new products. DocBuzz, Inc. will also benefit small, innovative pharmaceutical and biotechnology companies in North America that don’t have a large sales team.

1.3 Objectives

  • We aim to be a leading pharmaceutical e-detailing firm, focusing on medical professionals (i.e. physicians, nurse practitioners. physician assistants. dentists. podiatrists.
  • We will offer added value services such CME, current medical updates, and physician meeting rooms (chat room, bulletin board).
  • To hire staff both currently identified and unidentified to implement our business concept.
  • To sign up 5% more than 650K prescribing doctors by year 3, and provide 300K annual pharmaceutical detailing by year 3.
  • To reach a breakeven of $35.936 by the end year 2.
  • Sports Medical Equipment Business Plan


    Sports Medical Equipment Business Plan


    Professional Athletic Equipment, Inc., will manufacture and sell a protective device designed for young athletes. The brand name and identity for the product will be Body Armor. The product is designed to protect the abdomen, chest, and side from injury caused by blunt trauma. The device may also prevent sudden death by commotio Cordis (heart stoppage caused external trauma). This injury can occur in many sports, including baseball. The United States has filed a patent application for the device.

    This business plan is part our regular business planning process. This plan is reviewed semi-annually.

    In the next full-year, we will produce and market the initial product. To date, no sales have been made.

    We expect to sell 750 units per months on average during year one of our marketing campaigns. This will bring the total year’s sales volume to $242,550. Management predicts sales exceeding $4 million and profitability in year three. Before taxes, the expected year three profit is $593570.

    In order of importance, these are our keys to success for next year.

    • Initial product production for the first three sizes.
    • Basic research and testing marketing are key to product acceptance.
    • Multi-channel distribution is being tested.
    • Test marketing of media, PR, pricing, and product endorsement plans.
    • Goal of recouping production start-up costs and first year depreciation on initial three molds in year one.

    Then, there’s the rest:

    • Limiting loss to less that $200K for the second year
    • Reaching limited retail distribution in the third year (2nd sales year).
    • In the third year, achieve profitability.

    1.1 Objectives

    Professional Athletic Equipment, Inc. has set a modest goal for year one sales. These minimums will help us reach an over-all breakeven in year one. In year two, this will give us a platform for business expansion.

    Here are the sales targets for each size

    • Units as small as 4500
    • Medium’#82112250 units
    • Large–2250 units

    These targets will result in year-one sales volume of $242.550, which will confirm that the test was successful.

    The costs will be controlled in order to keep margins at these modest sales levels. To achieve growth, additional production and increased marketing activity may be necessary if sales exceed this goal. On the safe side, some sales may be missed in order to gear up for year two.

    1.2 Mission

    Professional Athletic Equipment, Inc., an American manufacturing and marketing company, is dedicated to protecting young athletes against tragic injury and death. We aim to produce quality products that have been tested and to earn a fair return on our investments. Our initial product, &#8220/Body Armor &#8221, will be sold to youth baseball players’ parents via targeted direct marketing. The #8220Body Armor aims to both prevent injury and enhance athletic performance through its confidence-enhancing qualities among youth sports participants. The #8220Body Armor#8221 is designed to encourage youth sports participation. We plan to expand the business and establish ourselves as an innovator and product leader in our niche. After our marketing platform is established, we will continue to finance internal and external growth. Once that happens, we will develop and acquire additional products. We will be a business that adheres to Christian values.

    1.3 Keys To Success

    Professional Athletic Equipment, Inc.’s success keys are:

    • High Quality Products. The new molds need to be created and production must begin. Initial orders must be placed and suppliers of all components identified. You must ensure that all components are delivered on time and assembled with minimal waste.
    • Marketing. Professional Athletic Equipment, Inc. can only be successful if the product is quality. The “Body Armor” is a brand new product. Consumers must be informed about its availability and purpose. The control of media costs is crucial to generating sales.
    • Management.

    While there is a temptation to grow a business exponentially, it is critical that Professional Athletic Equipment, Inc. management concentrate first on proving product salability within certain price points, margin requirements, distribution channels, and establish consumer acceptance. After these answers have been found, controlled expansion (which involves increased production and investments in inventory) can then be achieved with confidence.

    Medical Transcription Business Plan


    Medical Transcription Business Plan


    Elite Medical Transcription is a high-quality, low-error rate provider of medical transcriptions. EMT will concentrate on two market segments: physicians practicing alone and small practices of psychologists. These two segments are the most reliable users of outside transcription services. EMT will also service other markets that have more limited service needs.

    EMT will offer convenience and accuracy to Eugene’s physicians through the use advanced software. They will also require extensive training for their staff in order to ensure highly qualified transcribers.

    EMT will soon be recognized for its market leadership due to its competitive advantage and the growing market. The company will be profitable in eight months, and it will have a solid net income by year three.

    1.1 Objectives

    Elite Medical Transcription&#8217’s initial three years of operations have the following objectives:

    • To build a service-based business whose main goal is to exceed customer’s expectations.
    • Superior service is key to increasing the number of clients by 20 percent
    • To see 45% of our clients return to us again and again.
    • To create a home-based, sustainable business that lives off its own cash flow.

    1.2 Mission

    EMT’s mission is to provide the finest medical transcription service available. We are here to keep and attract new customers. All else will fall in line if we keep this maxim in mind.


    Medical Software Business Plan


    Medical Software Business Plan


    Overview

    AgaMatrix (a Boston-based venture in development) offers digital signal processing (DSP), technology that significantly improves the performance and functionality of biosensors. AgaMatrix core DSP algorithms are able to solve many immediate problems in medical devices by dramatically increasing the performance biosensors with minimal specialized hardware and other chemicals. AgaMatrix’s initial sales will be to medical device companies, specifically home glucose monitors as well as hospital point-of care blood analyzers. AgaMatrix anticipates achieving positive cash flow by year three with future target healthcare segments to include the large immunoassay and implantable biosensor sectors; as well as other vertical industries that heavily rely on biosensors, such as the military chemical agent detection, environmental air/water quality monitoring, and industrial processing sectors.

    Problem. Glucose Monitoring Systems Are Heavy and Painful To Use

    Because the home glucose monitoring is too painful or burdensome, many diabetic patients don’t use it as prescribed. Patient must insert the glucose biosensor into the glucose test strip four to seven time per day. The average testing compliance rate for diabetes is less than 1.5 per day. This causes complications like blindness or stroke and can accelerate the progression of these conditions, including heart and kidney disease. Diabetes is the most common cause of blindness for people aged 20 to 74. Therefore, better glucose monitoring compliance could be the biggest step towards prevention. Device manufacturers have identified that non-compliance stems from the physical pain experienced when using their devices. Therefore, they are looking for ways to decrease the size of the samples required by their devices. AgaMatrix technology provides less-invasive drawing tools to meet the growing demand for painful alternatives.

    Problems in the hospital blood analyzer market are more related to the lack of the comprehensiveness and accuracy of the devices, which results in reduced adoption levels. AgaMatrix’s value proposition for this market is very clear. Devices that are more sensitive and accurate will have a greater chance of being adopted more quickly.

    A Software Solutions for a Hardware Issue

    The biosensor device industry has tried to overcome issues such as accuracy, robustness, and sensitivity by improving the hardware (or chemical) aspects of its devices. For example, their chemical and biological design. By contrast, AgaMatrix is pioneering a software approach based on digital signal processing (DSP) algorithms that has a number of distinct practical advantages, including lower cost, easier/faster upgrade capability, and complementarity with respect to a wide variety of chemistry/hardware-based biosensor technologies.

    AgaMatrix’#8217;s solution consists of a series of software modules. This allows for new functionality, and dramatically improves performance of biosensors. You can leverage increased signal-to-noise ratios to lower blood sample requirements. For the professional healthcare market, AgaMatrix offers the ability to improve the overall accuracy and sensitivity of hospital point-of-care analyzers. This improves accuracy and is a key factor in the widespread adoption of portable lab equipment as a replacement for conventional laboratory equipment.

    Software DSP solutions have been vital to the success of many other industries where physical limitations would have impaired their growth. CD players, for example, relied on error-correction algorithms and oversampling in the 1980s to compensate low quality hardware filters. AgaMatrix’s algorithms provide analogous solutions in the biosensor space.

    Business Model: Software Licensing from Device Makers and Royalty Fees

    AgaMatrix, initially, will operate as technology licensing company. It will derive royalty revenue streams from device makers&#8217′ consumables sales. The technology will be sold to makers of home and hospital blood glucose analyzers as well as implantable and minimally invasive blood glucose biosensor developers.

    Therasense — An Illustration Of How Disruptive TheGlucose Marketplace Is

    Four major players dominated the blood sugar market a few decades ago (numbers are annual test strips revenue). Roche ($1.

    27B), J & J (1.09B), Bayer (650M), Abbot (545M) These companies have existed since the 1980’s. In the span of less than two years since their product roll-out, they have achieved $200 million in annual revenues, gone public, and now have a market capitalization of over $800 million. This is a market open to new technology, especially when it reduces pain.

    Competitive advantageThere is no direct competitor to our proprietary and highly innovative approach, which has been refined over the past seven year by our top-notch scientific team. AgaMatrix will complement any indirect competition that may be created by the major medical device manufacturer’s in-house laboratories. AgaMatrix holds the following competitive advantages.

    • Superior software paradigm complements the chemical (hardware), and technological advances in biosensors.
    • Over seven years of biosensor research, we have accumulated expertise.
    • Monopolization by the scientific team that invented the original paradigm.
    • Development lead time at least 2 years longer than the potential competition
    • Intellectual property strategy that includes two core utility patents (filed), and three defensive utility Patents.

    Customer Traction

    As potential customer targets, we have already spoken to two manufacturers who make blood glucose monitors as well as one manufacturer of hospital points-of-care devices. We have yet to approach more than 20 potential target companies. Here is a summary listing of all the companies we have reached.

    • Two blood glucose monitor companies expressed strong interest in becoming partners (discussions held with Presidents). Details are not disclosed at this time, but we expect to be able close a deal before June 2002.
    • A leading manufacturer of blood glucose monitors (J & J &#8211, discussions with Director-level personnel) and a leading manufacturer of hospital point-of care devices (i-STAT – discussions with Vice President and Director level staff).

    The Team

    A current team composed of:

    • The three leading scientists pioneering the use of digital signal processing to improve biosensor technology, with an aggregate of over 40 years of direct DSP/biosensor research experience.
    • Entrepreneurs who founded, built, and managed a software company for enterprise use.
    • An expanding group of veteran advisors consisting of doctors with healthcare business experience.
    • Three additional technical staff members have committed to the company’s success after seed financing. They are engineers from MIT or Tufts with more than 25 years of combined commercial engineering experience.

    Financing

    Since its inception, AgaMatrix was self-funded entirely by its principals. The company recently closed a seed round of $500K from a number of healthcare angel investors and IncTANK, an early stage venture capital fund. A Series A round in four to six months is expected, with an estimated $1 million.

    These funding rounds are designed to help you complete version 1.0 and acquire at least one customer during a period of thirteen months. We believe these milestones are reasonable, given current customer traction and product developments. The company is targeting to raise about $4million in institutional and private rounds by the end year one, which will be cashflow positive. Current valuation drivers include:

    • An elite scientific team including Dr. SridharIyengar, Dr. Justin Gooding, Dr. Ian Harding, and Dr. Sridhar Iyengar (CTO), as well as an aggressive business group with start-up or management experience.
    • Technology that is useful in a variety other vertical markets. It is protected by an IP strategy.
    • External validation through existing customer relationships and advancement in the final rounds of several national business planning competitions.

    1.1 Mission

    AgaMatrix designs solutions that power next-generation chemical and biological sensor systems. AgaMatrix provides a market-leading solution that dramatically increases the accuracy, sensibility, and robustness a range sensors. This is to help medical diagnostic devices be more effective.

    AgaMatrix’s technology is able to create devices that are painless and will satisfy the need for greater accuracy in medical diagnosis. It is committed to developing software solutions for a critical problem in hardware that affects millions upon millions of hospital patients and diabetics worldwide.

    1.2 Objectives

    • Design technology solutions that will increase adoption and compliance rates of diagnostic medical equipment by improving functionality and performance of biosensors.
    • By year three, you can achieve positive cash flow
    • In four years, you can reach $50,000,000 in annual revenues
    • Expand into other industries that heavily rely on biosensors, including industrial processing, environmental monitoring, and military sectors.

    Medical Equipment Business Plan


    Medical Equipment Business Plan


    MedNexis, Inc., which is the company, is a medical-device development company that has created and patented medical products it plans to market. With the assistance of biomedical and medical experts, a magnetic stimulator/field generator was created. One patent was initially filed.

    Allopathic Medicine

    One market addresses the unmet need for atrophy prevention/treatment in conditions that result in patient immobilization lasting more than two weeks. After two weeks, an average muscle has lost over 30% of its weight, which can lead to a longer time for complete recovery. MedStim, a novel and innovative design, was developed to meet this need. As further research into the benefits of pulsed electromagnetic fields becomes available, this device will likely be used in more ways. Pulsed field magnetism, for example, has been demonstrated in controlled trials to be an effective treatment to speed up the healing process of skeletal fractures.

    There is an existing market for magnetic stimulation devices in allopathic medical. However, this market is still embryonic and will continue to expand once the technology becomes cost-effective. This potential market has reached an estimated 4.2 million patients in the United States. MedStim, an innovative new device to target this market, has been created.

    Alternative Medicine

    Another market addresses the unmet need for a device with a stronger, more consistent therapeutic magnet field. The treatment of soft tissues with magnetic pulses using dynamic magnetic field therapy is believed to have positive effects on circulation and immune system function. These effects are proportional to the strength the magnetic field generates. TheraMag, a novel design to meet this demand for an enhanced therapeutic magnetic field in alternative medical treatment, has been created. This market exists today and has the potential to serve approximately 40,000,000 people in the United States at our beginning date.


    Technology

    Patent applications on the company’s first market entries have been filed using a patent agent specializing in biomedical device patents. MedNexis’#8217TM technology uses the principle that a magnet in a coil generates a magnetic fields which, in turn creates a current through any conductive materials within this field. This model has been used in diagnostic studies. Only single nerves have been stimulated with magnetism. MedNexis developed an electromagnetic device that will painlessly stimulate the muscles of humans to contract using this model. This technology has many uses. The following devices are the ones that were initially released:

    MedNexis’#8217’s patented device will be able to stimulate muscle effectively. This device will need higher electrical currents, more functionality and a wider range settings. This device will not be sold in the mainstream of allopathic medicine.

    TheraMag MedNexis’#8217’s patented device will heat tissue with a magnetic field. This will not cause contraction. This device will be used in other applications.


    Strategy

    MedNexis will target the following two markets: allopathic and alternative medicine. The devices will be named separately in order to distinguish them from possible negative connotations associated allopathic medicine.

    MedStim distribution will be through large distributors. This will make it easier to gain acceptance in this market. MedNexis&#8217, which is focusing on the market’s first efforts, will focus heavily on the production of controlled, randomized study data.

    TheraMag can be distributed to alternative medicine centres that are less centralized and direct sales will also possible. This market will not require any scientific proof. Entry to the market is possible as soon as the FDA issues an Investigational Device Exemption.

    Regulatory Issues

    You can get an Investigational Device Exemption for your product and clearly label it.

    FDA regulations will be followed and market entry will be made quickly. These products will be accepted based on the successful research results. This will greatly increase demand and open up new markets.


    Major Milestones

    Research and Development at the animal stage is ongoing, in the first year of one.

    • In the middle year one, extend patent coverage to Australia (Europe) and Canada (Canada).
    • Human clinical trials underway, middle Year Two.
    • Published research studies, year two
    • TheraMag available for purchase, year one
    • MagnaStim is available for purchase, marked ‘For Investigational Purpose Only’ at the end of Year 2.
    • Year Four sees the establishment of profitability.


    Competitive advantage

    While the MagnaStim and TheraMag devices are effective and user-friendly, with multiple home healthcare applications, all the competing devices currently on the market are only partially effective or difficult and awkward to use for the recommended therapeutic treatment. MedNexis will use its patented designs to fill the need in the market for an easier to use, more effective magnetic stimulator/field generator.


    Financial

    According to financial projections, the company will be profitable by year 3 if it receives $750,000 in funding. The company projects $23.5million in sales with a remarkable net profit in Year 3. These projections are based on penetration of less that 3% in each market segment.

    Medical Scanning Lab Business Plan


    Medical Scanning Lab Business Plan


    Scan Lab Medical Imaging offers a wide range medical image scanning services for New Bedford, Massachusetts.

    The Market

    Scan Lab will target insurance carriers. To set up contracts for medical scanning service providers, insurance companies will use a process called a submittal. Because 99% are billed by insurance, these contacts are essential in today’s medical world. This process is governed by insurance companies. Scan Lab understands how important it is to get insurance companies approved and will work hard in order to get approval for all the popular insurance plans.

    Once Scan Lab has been approved by an insurance company, it will rely on referrals of physicians to point their patients to Scan Lab. Doctors may refer patients based on a variety of factors, such as geographical location/convenience, types of scans, accepted insurance plans, and other factors. It is crucial to establish strong marketing and sales campaigns to alert doctors to Scan Lab&#8217.



    Scan Lab provides a wide variety of radiology-based, medical scanning tests. Scan Lab offers the most advanced equipment and expert medical training to assist physicians in referring patients to Scan Lab.

    Management

    Dr. Carolyn Jones will manage Scan Lab. Dr. Jones is a radiology specialist who received her medical education at the University of California San Diego. Dr. Jones performed her residency at John Hopkins, also nationally recognized for their radiology program. Dr. Jones has been practicing radiology in Boston for 13 years.

    1.1 Mission

    Scan Lab is determined to be New Bedford’s leader in medical scan technology. This will be achieved by friendly service, flexible acceptance of insurance plans, and accurate analysis.

    1.2 Objectives

    • To capture 40% within two years.
    • To reach profitability within two years.
    • To double sales in the third year.

    Success keys 1.3

    • Only buy medical equipment that is in high demand within your community.
    • Provide friendly, prompt service with accurate readings
    • You must maintain strict financial control to reduce the capital cost of medical imaging equipment.


    Medical Language Translation Business Plan


    Medical Language Translation Business Plan


    Biomedical innovation has a worldwide audience. Each new innovation, each new medical/pharmaceutical product, has a world-wide market. This creates a unique challenge for companies trying to develop translations in the areas below:

    • Instructions for usage
    • User’s manuals.
    • Service manuals.
    • Packaging/labels.
    • Clinical trials
    • Regulatory documents.
    • Marketing materials

    Translation services are needed that are proficient in both technical and local languages. Global Health Translations can be a great resource when preparing a product to go on the international market. We offer medical translation in these areas:

    • Medical devices.
    • Pharmaceuticals.
    • Biotechnology.

    1.1 Mission

    The mission of Global Health Translations is to provide our clients translators that can master the medical concepts in the material as well as the demands of the language translation.

    1.2 Keys to Success

    • All translations will undergo a review by industry professionals.
    • Selection of certified translators with a university diploma from their native country.
    • Project management is professional, efficient, and fast.

    1.3 Objectives

    Global Health Translations’ objectives are:

    • Translating translations of extraordinary quality.
    • Assuring fast turnaround on every project.
    • Maintenance of competitive prices